SCHEMBL1606388

SCHEMBL1606388

CC(C)S(=O)(=O)NCc1cncc(-c2cc3ccccc3n2C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 6/20 0.53
KMT2A Q03164 2/20 0.43
CHRNB1 P11230 1/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNB3 Q05901 1/20 0.42
APP P05067 3/20 0.40
CYP11B1 P15538 2/20 0.38
CYP19A1 P11511 1/20 0.38
PTGES2 Q9H7Z7 1/20 0.37
IDO1 P14902 1/20 0.37
NAMPT P43490 1/20 0.37
TRPV3 Q8NET8 1/20 0.36
NPY5R Q15761 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
STAT6 P42226 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1606086 0.88 CYP11B2 (0.55) CYP11B2KMT2ACHRNB1CHRNB2CHRNB4
SCHEMBL1605531 0.87 CYP11B2 (0.69) CYP11B2KMT2ACHRNB1CHRNB2CHRNB4
SCHEMBL1606653 0.86 CYP11B2 (0.57) CYP11B2CYP11B1CYP19A1NPY5RALDH1A1
SCHEMBL1607295 0.84 CYP11B2 (0.55) CYP11B2KMT2ACHRNB1CHRNB2CHRNB4
SCHEMBL30384472 0.84 CYP11B2 (0.52) CYP11B2KMT2ACHRNB1CHRNB2CHRNB4
SCHEMBL1606989 0.84 CYP11B2 (0.52) CYP11B2KMT2ACHRNB1CHRNB2CHRNB4
SCHEMBL1605878 0.80 KMT2A (0.55) CYP11B2KMT2ACHRNB1CHRNB2CHRNB4
SCHEMBL6125512 0.79 KMT2A (0.44) CYP11B2KMT2ACHRNB1CHRNB2CHRNB4
SCHEMBL19417509 0.78 CYP11B2 (0.43) CYP11B2KMT2ACHRNB1CHRNB2CHRNB4
SCHEMBL14603921 0.76 KMT2A (0.46) CYP11B2KMT2ACHRNB1CHRNB2CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307371-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2017-10-04 EP disclosed
EP-2307371-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2017-10-04 EP disclosed
US-9242963-B2 Organic compounds NOVARTIS AG (CH) 2016-01-26 US disclosed
US-9242963-B2 Organic compounds NOVARTIS AG (CH) 2016-01-26 US disclosed
US-20150210672-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2015-07-30 US disclosed
US-20150210672-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2015-07-30 US disclosed
CN-104193725-A ORGANIC COMPOUNDS NOVARTIS AG 2014-12-10 CN disclosed
US-20140288126-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2014-09-25 US disclosed
US-20140288126-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2014-09-25 US disclosed
CN-102076665-B Organic compounds NOVARTIS AG 2014-09-03 CN disclosed
US-8791141-B2 Organic compounds NOVARTIS AG (CH) 2014-07-29 US disclosed
US-8030334-B2 Organic compounds NOVARTIS AG (CH) 2011-10-04 US disclosed
US-8030334-B2 Organic compounds NOVARTIS AG (CH) 2011-10-04 US disclosed
US-8030334-B2 Organic compounds NOVARTIS AG (CH) 2011-10-04 US disclosed
US-20110082129-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-04-07 US disclosed
US-20110082129-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-04-07 US disclosed
US-20100261698-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-10-14 US disclosed
US-20100261698-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-10-14 US disclosed
US-20100261698-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-10-14 US disclosed
WO-2009156462-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082129-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 CYP11B2 13/4885KMT2A 4447/4885CHRNB1 2629/4885
US-20100261698-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 CYP11B2 13/4885KMT2A 4447/4885CHRNB1 2629/4885
US-20150210672-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 CYP11B2 12/4885KMT2A 4274/4885CHRNB1 3239/4885
US-20140288126-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 CYP11B2 12/4885KMT2A 4274/4885CHRNB1 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.